Clinical Trial: A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstrom's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07231952) titled 'A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstrom's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)' on Nov. 13.

Brief Summary: The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)

Study Start Date: Nov. 11

Study Type: INTERVENTIONAL

Condition: Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma

Intervention: DRUG: Pirtobrutinib

PO QD

DRUG: Venetoclax

PO QD

DRUG: Rituximab

IV or SC

Recruitment Status: RECRUITING ...